ANAB (AnaptysBio) LT-Debt-to-Total-Asset : 0.03 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is AnaptysBio LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. AnaptysBio's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.03.

AnaptysBio's long-term debt to total assets ratio declined from Sep. 2023 (0.03) to Sep. 2024 (0.03). It may suggest that AnaptysBio is progressively becoming less dependent on debt to grow their business.

AnaptysBio LT-Debt-to-Total-Asset Historical Data

The historical data trend for AnaptysBio's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AnaptysBio LT-Debt-to-Total-Asset Chart

AnaptysBio Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.04

AnaptysBio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.04	0.04	0.04	0.03

AnaptysBio LT-Debt-to-Total-Asset Calculation

AnaptysBio's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	16.037	/	452.389
	=	0.04

AnaptysBio's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	14.607	/	493.418
	=	0.03

AnaptysBio (NAS:ANAB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

AnaptysBio LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of AnaptysBio's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

AnaptysBio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AnaptysBio Inc (NAS:ANAB) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

0HFQ:UK AN6:Germany

Address

10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121

Website

https://www.anaptysbio.com

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Executives

Hollings Renton	director
Paul F. Lizzul	officer: Chief Medical Officer	30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Eric J Loumeau	officer: General Counsel	C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121
Dennis Mulroy	officer: Chief Financial Officer
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Dennis M Fenton	director
Daniel Faga	director	3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
John A Orwin	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Hamza Suria	director, officer: President, CEO	C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Oleg Nodelman	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Magda Marquet	director	ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
J. Anthony Ware	director	C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121
Laura Hamill	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Marco Londei	officer: Chief Medical Officer	C/O ANAPTYSBIO, INC., 10421 PACIFIC CENTER COURT, SUITE 200, SAN DIEGO CA 92121